ClinicalTrials.gg
CompletedNCT01761773Updated Sep 22, 2014

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

A Phase 1 interventional study of cabozantinib in Healthy and Renal Impairment, sponsored by Exelixis. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-22.

Sponsored by Exelixis · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
216th of 468
32 · median 32
Started
2012
with 22 others
Phase 1
232 of 553
14 open now
Registered
235th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 216th largest by enrollment of the 468 interventional ones that give a count, is one of 23 that started in 2012, is one of 232 in phase 1, and was the 235th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The main objective of the trial is to compare the pharmacokinetics of a 60 mg dose of cabozantinib in adult subjects with impaired renal function compared with healthy adult subjects. Another objective is to assess the safety and tolerability of cabozantinib in these adult subjects.

03

Conditions studied

  • Healthy
  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight must be ≥ 50 kg and \< 130 kg with a ≤ 38.0 (kg/m2).
  • Must use acceptable form of during the course of the study and for 3 months following the single dose of study drug.
  • Female subjects of must have a negative pregnancy test at screening and check-in.
  • Negative test for ; hepatitis A, B, and C.
  • Must have adequate vital sign reads at screening and check-in.
  • Must be able to comply with dietary and fluid restrictions required for the study.

Exclusion criteria

Exclusion Criteria:

  • History of medical or surgical conditions that would interfere with GI absorption, distribution, metabolism, or excretion of the study drug.
  • Recent clinical evidence of pancreatic injury.
  • Recent use of drugs known to significantly inhibit or induce P450 enzymes.
  • Previous diagnosis of .
  • Unwilling to forgo use of any over-the-counter or non-prescription preparations.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Group 1

    Subjects with normal renal function: healthy normal adult subjects with an eGFR ≥ 90 mL/min/1.73m2.

    Drug: cabozantinib

  • Experimental
    Group 2

    Subjects with mild renal impairment: adult subjects with a eCFR ≥ 90 mL/min/1.73m2.

    Drug: cabozantinib

  • Experimental
    Group 3

    Moderate renal impairment: adult subjects with an eGFR between ≥30 - ≤ 59 mL/min/1.73m2.

    Drug: cabozantinib

  • Experimental
    Group 4

    Severe renal impairment: adult subjects with an eGFR ≤ 29 mL/min/1.73m2, not on dialysis.

    Drug: cabozantinib

Interventions

  • 3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.

    Also known as: XL184

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics

    AUC, Cmax, tmax, kel, t1/2, CL/F, V/F and fu as measure of a single oral 60 mg dose of cabozantinib in adults with impaired renal function compared with healthy subjects matched for age, gender, and body mass index (BMI). Subjects will receive a single oral 60 mg dose of cabozantinib on Day 1 and then undergo periodic assessments Days 1 - 8 following this single dose, as well as on the mornings of Days 11, 13, 15, 18, 21, 22.

    Time frame: Days 1 - 8 as well as the morning of Days 11, 13, 15, 18, 21, 22.

Secondary outcomes

  1. Safety and Tolerability

    Number of participants with adverse events, serious adverse events, and laboratory abnormalities as a measure of the safety and tolerability of a single oral 60 mg dose in adult subjects with impaired renal function and in healthy adult subjects.

    Time frame: Days 1 - 8 and Days 11, 13, 15, 18, 21, 22.

07

Study locations

3 sites
  • Miami, Florida 33136, United States
  • Orlando, Florida 32809, United States
  • Neptune, New Jersey 07753, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Apr 2013 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2013
First posted
Jan 7, 2013
Start
Dec 2012
Primary completionActual
Apr 2013
CompletionActual
Jul 2014
Last update
Sep 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01761773
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Jan 7, 2013
Start date
Dec 2012
Primary completion
Apr 2013
Completion
Jul 2014
Last update
Sep 22, 2014

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion